Is Rhythm Pharmaceuticals (RYTM) Undervalued On Fresh Setmelanotide Data?

Rhythm Pharmaceuticals (RYTM) is back in focus after new clinical data on setmelanotide were shared at the European Society for Paediatric Endocrinology meeting, highlighting outcomes in children with rare hypothalamic obesity.

Rhythm Pharmaceuticals’ recent clinical updates come at a more challenging time for the shares, which have fallen 15.6% on a 30-day share price return and 6.9% on a year-to-date basis. However, the 1-year total shareholder return is slightly positive and the 3-year total shareholder return remains very large. This suggests that long-term holders are still sitting on substantial gains, despite fading near-term momentum.

Scan for other Rhythm Pharmaceuticals style rare-disease plays by reviewing the hand-picked 16 high quality undiscovered gems that have strong fundamentals yet remain off most investors’ radar.

Rhythm Pharmaceuticals now combines a sharp pullback with fresh clinical momentum, creating a straightforward tension. After this reset, does the current valuation still compensate you for the execution and funding risks ahead?

Most Popular Narrative: 27.1% Undervalued

Rhythm Pharmaceuticals closed at $97.71, while the most followed narrative pegs fair value at $134. That gap frames the current debate over how much of the rare-disease opportunity is already recognized in the share price.

Rhythm Pharmaceuticals is a high-growth commercial-stage company targeting orphan neuroendocrine disorders linked to MC4R pathway dysfunction (genetic obesity). Having expanded from one disorder to multiple approved indications, the company has additional opportunities ahead to expand its portfolio. I rate RYTM a BUY, driven by expected double-digit revenue growth, a broader targeted-obesity portfolio, and stronger-than-expected patient uptake.

See why 5 investors see Rhythm Pharmaceuticals as 27% undervalued.

Result: Fair Value of $134 (UNDERVALUED)

Still, the Rhythm Pharmaceuticals story can break if clinical timelines slip, or if funding the broader pipeline leads to heavier than expected dilution or costs.

Find out about the key risks to this Rhythm Pharmaceuticals narrative.

Another View on Rhythm Pharmaceuticals’ Valuation

The first fair value lens paints Rhythm Pharmaceuticals as undervalued, yet the simple revenue multiple tells a tougher story. At a P/S of 28x, the stock trades at more than double the US Biotechs average of 12.6x and well above a fair ratio of 17.1x.

That gap leaves less room for error if expectations around growth or profitability timing change. It also raises the question of whether investors are paying tomorrow’s price today.

For a closer look at how these revenue multiples stack up against peers and what that could mean for risk and reward, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

After all this, do you see Rhythm Pharmaceuticals as priced for promise or already rich on optimism, and are you prepared to move quickly and pressure test that view against the underlying data? To weigh those positives for yourself, start with the 3 key rewards

Looking for more Rhythm Pharmaceuticals style ideas?

Do not stop with Rhythm Pharmaceuticals. Use the Simply Wall Street Screener to pressure test your thesis and uncover fresh opportunities before the crowd catches on.

• Target potential mispricings by scanning a curated pool of companies that combine quality and value through the 33 high quality undervalued stocks.
• Build a watchlist that aims for resilience first by reviewing the 30 resilient stocks with low risk scores and focusing on businesses with steadier risk profiles.
• Strengthen your income toolkit by checking the 6 dividend fortresses and narrowing in on companies offering higher yields with staying power.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com